Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc (CTXR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 226,413
  • Shares Outstanding, K 125,785
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,550 K
  • 60-Month Beta 1.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.66
Trade CTXR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.09
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6800 +2.08%
on 04/15/21
2.2000 -22.05%
on 03/24/21
-0.3550 (-17.15%)
since 03/15/21
3-Month
1.1200 +53.13%
on 01/19/21
2.9000 -40.86%
on 02/22/21
+0.5850 (+51.77%)
since 01/15/21
52-Week
0.6400 +167.97%
on 04/21/20
2.9000 -40.86%
on 02/22/21
+1.0151 (+145.04%)
since 04/15/20

Most Recent Stories

More News
Citius Pharmaceuticals to Highlight its Phase 3 Clinical Trial Product Mino-Lok® at Benzinga Biotech Small Cap Conference on March 25

, /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, will participate...

CTXR : 1.7400 (-3.33%)
Real Chemistry and the Media Empathy Foundation Partner at SXSW, Launching "Culture Care" to Reduce Disease-Related Stigma and Bias Through Data-Driven Creative Content

Global health innovation company Real Chemistry announced today at the 2021 SXSW Healthcare Media Lounge that it is partnering with the non-profit Media Empathy Foundation to deliver "Culture Care" engagement...

CTXR : 1.7400 (-3.33%)
Thinking about buying stock in Cardiff Oncology, Nio, Intuit, Accenture, or Citius Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRDF, NIO, INTU, ACN, and CTXR.

CRDF : 8.81 (+0.11%)
CTXR : 1.7400 (-3.33%)
INTU : 417.92 (+1.61%)
ACN : 285.12 (+0.24%)
NIO : 35.64 (-3.73%)
Thinking about buying stock in Nio, Norwegian Cruise Line, Immunovant, Devon Energy, or Citius Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, NCLH, IMVT, DVN, and CTXR.

IMVT : 16.15 (+1.44%)
CTXR : 1.7400 (-3.33%)
DVN : 22.35 (-0.62%)
NCLH : 28.58 (-2.16%)
NIO : 35.64 (-3.73%)
Citius Pharmaceuticals to Feature Product Candidates Including Stem-Cell Therapy for COVID-19-Related Acute Respiratory Conditions at H.C. Wainwright Global Life Sciences Conference March 9-10

, /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced...

CTXR : 1.7400 (-3.33%)
Thinking about buying stock in BlackBerry, Express, Norwegian Cruise Line, Citius Pharmaceuticals, or Verizon?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BB, EXPR, NCLH, CTXR, and VZ.

CTXR : 1.7400 (-3.33%)
BB : 8.77 (-2.56%)
EXPR : 3.36 (-3.72%)
NCLH : 28.58 (-2.16%)
VZ : 57.75 (+0.09%)
Thinking about buying stock in Workhorse Group, Globalstar, Palantir Technologies, Marathon Oil, or Citius Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WKHS, GSAT, PLTR, MRO, and CTXR.

GSAT : 1.0450 (-5.86%)
CTXR : 1.7400 (-3.33%)
WKHS : 11.75 (-6.67%)
MRO : 10.88 (-1.89%)
PLTR : 23.24 (-1.94%)
Extensive Demand for T-Cell Adoptive Immunotherapy Rising with Growing Prevalence of Cancer

PALM BEACH,  Fla., /PRNewswire/ -- In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue...

ONCY : 2.98 (-2.93%)
ONC.TO : 3.73 (-3.37%)
VCNX : 2.42 (-3.59%)
PDSB : 5.04 (-4.00%)
CTXR : 1.7400 (-3.33%)
CLVS : 6.09 (-2.56%)
Thinking about buying stock in Celsion Corp, Can Fite Biopharma, ConforMIS Inc, Citius Pharmaceuticals, or Vuzix Corp?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSN, CANF, CFMS, CTXR, and VUZI.

CANF : 2.19 (-3.52%)
CFMS : 0.8256 (-1.71%)
CLSN : 1.1800 (-5.60%)
CTXR : 1.7400 (-3.33%)
VUZI : 23.68 (-8.22%)
Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

, /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today...

CTXR : 1.7400 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 1.9267
2nd Resistance Point 1.8733
1st Resistance Point 1.8367
Last Price 1.7400
1st Support Level 1.7467
2nd Support Level 1.6933
3rd Support Level 1.6567

See More

52-Week High 2.9000
Fibonacci 61.8% 2.0367
Fibonacci 50% 1.7700
Last Price 1.7400
Fibonacci 38.2% 1.5033
52-Week Low 0.6400

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar